This review highlights that while general care for chemotherapy-induced hand-foot syndrome is consistent across guidelines, pharmacological management varies, indicating a need for updated evidence-based recommendations.
Answers are grounded in this paper and cite their sources.
Clinicians can follow consistent general skin care advice now; this review challenges pharmacological variability and extends the call for updated evidence-based guidelines.
INTRODUCTION/BACKGROUND: Hand-foot syndrome (HFS) is a common side effect of chemotherapy drugs such as 5-fluorouracil and capecitabine, impairing daily function and quality of life. This study aimed to compare international clinical guidelines regarding assessment and management of HFS to identify areas of consensus and divergence and evidence gaps. METHODS: Guidelines were identified through PubMed (from inception to February 2025), with a supplementary search on Google. Only the most recent versions of English guidelines were included. Data extraction focused on the guideline methodology and recommendations on the prevention, assessment, and management of HFS. Each guideline was critically appraised using the AGREE II checklist. RESULTS: Six guidelines were identified authored by the following cancer agencies: British Columbia Cancer (BCC), European Society of Medical Oncology (ESMO), Cancer Institute NSW (eviQ), Oncology Nursing Society (ONS), United Kingdom Oncology Nursing Society and Acute Oncology (UKONS AO), and United Kingdom North Cancer Alliance (UKNCA). Regarding prevention, five of six guidelines (83%) advised avoiding chemical and physical stressors to the hands and feet and using alcohol-free moisturizer. Only ESMO, BCC, and eviQ recommended oral celecoxib to prevent capecitabine-induced HFS. ESMO and ONS recommended cooling procedures to prevent taxane-induced HFS. Likewise, BCC and eviQ recommend cooling procedures for all agents. All guidelines except ONS recommended dose suspension with grade 2 or 3 HFS and continuation when resolved or improved. ESMO and BCC recommended topical corticosteroids for grade 1 HFS, ESMO for grade 2 or 3, and eviQ for prophylactic use. Finally, BCC and ESMO suggested to consider oral dexamethasone for PEGylated doxorubicin-induced HFS. CONCLUSION: While general skin care and dose modification guideline recommendations were consistent, pharmacological recommendations varied. Guidelines are key for healthcare professionals in supporting patients with HFS. Therefore, regular updates with emerging evidence for interventions such as topical diclofenac are needed to ensure the quality of care.
No takes yet. Share an insight, caveat, or question.
Sferrazza et al. (2026) studied Skin toxicity associated with systemic anti-cancer therapy. Skin toxicity management protocols was evaluated. Standardized clinical guidelines for systemic anti-cancer therapy-associated skin toxicities provide graded management strategies for hand-foot syndrome, acneiform rash, and other dermatological adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: